Oxaliplatin induced laryngospasm: a case series

Oxaliplatin is a third-generation platinum derivative used as a first-line agent in the treatment of colorectal carcinoma, biliary tract cancer and gastric cancers and can be used as a neoadjuvant/adjuvant in these cancers. The dose limiting toxicity is peripheral neuropathy, others include hypersensitivity reactions, haematological toxicity and pulmonary fibrosis. Hypersensitivity reactions can extend from milder reactions like urticaria, rash to severe symptoms like hypotension and laryngospasm. The laryngospasm due to oxaliplatin is reported to be reversible with corticosteroids, antihistamines and oxygen. This case series suggest that oxaliplatin has a propensity to cause severe hypersensitivity reaction presenting as laryngospasm not with a single dose but with subsequent doses of oxaliplatin. Prompt symptomatic treatment with corticosteroids leads to reversal of symptoms and improvement in the condition of the patient.

Download Full-text

P5-5 Phase 2/3 study of bintrafusp alfa with gemcitabine plus cisplatin as first-line treatment of biliary tract cancer

Annals of Oncology ◽

10.1016/j.annonc.2021.05.684 ◽

2021 ◽

Vol 32 ◽

pp. S333

Author(s):

Do-Youn Oh ◽

Filippo de Braud ◽

John Bridgewater ◽

Junji Furuse ◽

Chih-Hung Hsu ◽

...

Keyword(s):

Biliary Tract ◽

Biliary Tract Cancer ◽

Line Treatment ◽

Phase 2 ◽

First Line ◽

Tract Cancer ◽

First Line Treatment

Download Full-text

Autoimmune Hemolytic Anemia as a Complication of Congenital Anemias. A Case Series and Review of the Literature

Journal of Clinical Medicine ◽

10.3390/jcm10153439 ◽

2021 ◽

Vol 10 (15) ◽

pp. 3439

Author(s):

Irene Motta ◽

Juri Giannotta ◽

Marta Ferraresi ◽

Kordelia Barbullushi ◽

Nicoletta Revelli ◽

...

Keyword(s):

Hemolytic Anemia ◽

Autoimmune Hemolytic Anemia ◽

Case Series ◽

Intravenous Immunoglobulins ◽

Point Of View ◽

First Line ◽

Human Erythropoietin ◽

Immune Mediated ◽

Hemolytic Crisis ◽

Life Threatening

Congenital anemias may be complicated by immune-mediated hemolytic crisis. Alloantibodies are usually seen in chronically transfused patients, and autoantibodies have also been described, although they are rarely associated with overt autoimmune hemolytic anemia (AIHA), a serious and potentially life-threatening complication. Given the lack of data on the AIHA diagnosis and management in congenital anemias, we retrospectively evaluated all clinically relevant AIHA cases occurring at a referral center for AIHA, hemoglobinopathies, and chronic hemolytic anemias, focusing on clinical management and outcome. In our cohort, AIHA had a prevalence of 1% (14/1410 patients). The majority were warm AIHA. Possible triggers were recent transfusion, infection, pregnancy, and surgery. All the patients received steroid therapy as the first line, and about 25% required further treatment, including rituximab, azathioprine, intravenous immunoglobulins, and cyclophosphamide. Transfusion support was required in 57% of the patients with non-transfusion-dependent anemia, and recombinant human erythropoietin was safely administered in one third of the patients. AIHA in congenital anemias may be challenging both from a diagnostic and a therapeutic point of view. A proper evaluation of hemolytic markers, bone marrow compensation, and assessment of the direct antiglobulin test is mandatory.

Download Full-text

Gemcitabine-Containing Chemotherapy for the Treatment of Metastatic Myxofibrosarcoma Refractory to Doxorubicin: A Case Series

Current Oncology ◽

10.3390/curroncol28010078 ◽

2021 ◽

Vol 28 (1) ◽

pp. 813-817

Author(s):

Arielle Elkrief ◽

Suzanne Kazandjian ◽

Thierry Alcindor

Keyword(s):

Overall Survival ◽

Soft Tissue ◽

Soft Tissue Sarcoma ◽

Objective Response ◽

Case Series ◽

Progression Free Survival ◽

Distant Metastases ◽

First Line ◽

Pleomorphic Sarcoma ◽

Line Setting

Background: Myxofibrosarcoma is a type of soft-tissue sarcoma that is associated with high rates of local recurrence and distant metastases. The first-line treatment for metastatic soft-tissue sarcoma has conventionally been doxorubicin-based. Recent evidence suggests that myxofibrosarcoma may be molecularly similar to undifferentiated pleomorphic sarcoma (UPS), which is particularly sensitive to gemcitabine-based therapy. The goal of this study was to evaluate the activity of gemcitabine-containing regimens for the treatment of metastatic myxofibrosarcoma refractory to doxorubicin. Material and Methods: We retrospectively evaluated seven consecutive cases of metastatic myxofibrosarcoma at our institution treated with gemcitabine-based therapy in the second-line setting, after progression on doxorubicin. Baseline clinical and baseline characteristics were collected. Primary endpoints were objective response rate (ORR), progression-free survival (PFS) and overall survival (OS). Results: After progression on first-line doxorubicin, a partial, or complete radiological response was observed in four of seven patients who received gemcitabine-based chemotherapy. With a median follow-up of 14 months, median progression-free and overall survival were 8.5 months and 11.4 months, respectively. Conclusions: Gemcitabine-based chemotherapy was associated with encouraging response rates in this cohort, similar to those seen in UPS. Both entities could be studied together for novel gemcitabine-based regimens.

Download Full-text

In Regard to “A Phase Ib Study of NUC ‐1031 in Combination with Cisplatin for the First‐Line Treatment of Patients with Advanced Biliary Tract Cancer ( ABC ‐08)”

The Oncologist ◽

10.1002/onco.13703 ◽

2021 ◽

Cited By ~ 3

Author(s):

Angela Dalia Ricci ◽

Alessandro Rizzo ◽

Giovanni Brandi

Keyword(s):

Biliary Tract ◽

Biliary Tract Cancer ◽

Line Treatment ◽

First Line ◽

Phase Ib ◽

Tract Cancer ◽

First Line Treatment

Download Full-text

A prognostic model in patients with advanced biliary tract cancer receiving first-line chemotherapy

Acta Oncologica ◽

10.1080/0284186x.2021.1953704 ◽

2021 ◽

pp. 1-8

Author(s):

Roberto Filippi ◽

Francesco Montagnani ◽

Pasquale Lombardi ◽

Lorenzo Fornaro ◽

Giuseppe Aprile ◽

...

Keyword(s):

Biliary Tract ◽

Biliary Tract Cancer ◽

Prognostic Model ◽

First Line ◽

Tract Cancer ◽

Line Chemotherapy

Download Full-text

FIRST CASE SERIES OF VENOUS SINUS STENTING IN IIH PATIENTS IN WALES

Journal of Neurology Neurosurgery & Psychiatry ◽

10.1136/jnnp-2015-312379.25 ◽

2015 ◽

Vol 86 (11) ◽

pp. e4.113-e4

Author(s):

Gauhar Abbas Malik ◽

Yogish Joshi

Keyword(s):

Intracranial Hypertension ◽

Case Series ◽

Headache Disorder ◽

Venous Sinus ◽

First Line ◽

Venous Stenting ◽

First Case ◽

Sinus Stenosis

BackgroundIdiopathic Intracranial Hypertension (IIH), is defined by increased cerebral spinal fluid (CSF) pressure in the absence of other causes of intracranial hypertension. There has been recent interest in the role of intracranial venous sinus stenosis in IIH. The raised pressures in IIH are argued to worsen by the secondary appearance of the venous sinus stenosis.Objective5 patients have undergone endovascular pressure measurement in Wales and their clinical details including history, examination, initial management, neuroimaging pre- and post venous stenting, and follow-up (6–24 months) to provide the first case study of patients undergoing Venous sinus stenting in Wales.Methods5 patients with IIH refractory to first line treatments underwent venography and manometry and 4 patients underwent stenting of the venous sinuses after this procedure had shown a pressure gradient proximal to stenosis in the lateral sinuses.ResultsThree patients were rendered asymptomatic, two were improved including one patient unmasking a different headache disorder following treatment.ConclusionsStenting in venous stenosis provides a further treatment option to patients refractory to first line treatments with IIH. This case series highlights in selected cases treatment is promising with good outcomes.

Download Full-text